Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | ABL2 | P42684 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | KIF5B | P33176 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27217844 | 0.97 | SRC (0.40) | SRCEGFRRIPK2ABL1ABL2 | |
| SCHEMBL30813564 | 0.96 | SRC (0.41) | SRCEGFRRIPK2ABL1ABL2 | |
| SCHEMBL27217745 | 0.93 | SRC (0.38) | SRCEGFRABL1ABL2 | |
| SCHEMBL30813574 | 0.93 | SRC (0.40) | SRCEGFRRIPK2ABL1ABL2 | |
| SCHEMBL27217970 | 0.92 | SRC (0.40) | SRCEGFRRIPK2ABL1ABL2 | |
| SCHEMBL27217994 | 0.92 | SRC (0.44) | SRCEGFRABL1ABL2 | |
| SCHEMBL27217748 | 0.91 | SRC (0.46) | SRCEGFRRIPK2ABL1ABL2 | |
| SCHEMBL30813442 | 0.89 | SRC (0.49) | SRCEGFRABL1ABL2 | |
| SCHEMBL27217705 | 0.89 | SRC (0.49) | SRCEGFRABL1ABL2 | |
| SCHEMBL30813445 | 0.89 | RIPK2 (0.41) | SRCEGFRRIPK2RETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | SRC 1597/4885EGFR 4857/4885RIPK2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.